GA01201

Lapatinib is an orally active drug for breast cancer and other solid tumours. It is a dual tyrosine kinase inhibitor which interrupts the HER2/neu and epidermal growth factor receptor (EGFR) pathways. It is used in combination therapy for HER2-positive breast cancer.

We have successfully synthesized standards of the Lapatinib. This will be of interest to pharmaceutical companies and analytical labs.